Cytokinetics Among Windhover’s 2011 “Top Biopharma Projects to Watch”

Cytokinetics is among the elite group of high-value asset companies chosen by Windhover to present at the upcoming therapeutics partnering conference next week in Boston. Cytokinetics’ muscle enhancing drug, CK-2017357, has been shown to be safe in ALS patients and is now being studied for efficacy in a Phase IIa clinical trial.

Click here to read more.

Share this: